{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatocellular+carcinoma&page=25",
    "query": {
      "intervention": "Hepatocellular carcinoma",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 747,
    "total_pages": 75,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatocellular+carcinoma&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatocellular+carcinoma&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T00:16:31.850Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05775159",
      "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Volrustomig",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 294,
      "start_date": "2023-04-24",
      "completion_date": "2027-10-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05775159"
    },
    {
      "nct_id": "NCT05366829",
      "title": "Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular",
        "Liver Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2022-07-25",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey • The Bronx, New York",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05366829"
    },
    {
      "nct_id": "NCT02859324",
      "title": "A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "CC-122",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2016-09-20",
      "completion_date": "2020-03-27",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Gainesville, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859324"
    },
    {
      "nct_id": "NCT03026803",
      "title": "A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer",
        "Hepatocellular Cancer"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2006-11",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-04-13",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03026803"
    },
    {
      "nct_id": "NCT02560779",
      "title": "Trial of TRC105 and Sorafenib in Patients With HCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carotuximab (TRC105)",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tracon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2016-11",
      "completion_date": "2019-08",
      "has_results": true,
      "last_update_posted_date": "2020-07-17",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Cleveland, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02560779"
    },
    {
      "nct_id": "NCT03748927",
      "title": "Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Year to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-04-08",
      "completion_date": "2020-03-23",
      "has_results": false,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03748927"
    },
    {
      "nct_id": "NCT00862082",
      "title": "Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "PR104 550 mg/m^2 + sorafenib",
          "type": "DRUG"
        },
        {
          "name": "PR104 770 mg/m^2 + sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Proacta, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2009-03",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-23",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00862082"
    },
    {
      "nct_id": "NCT00427973",
      "title": "AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer"
      ],
      "interventions": [
        {
          "name": "cediranib maleate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "dynamic contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2009-05",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2016-10-31",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00427973"
    },
    {
      "nct_id": "NCT02460991",
      "title": "A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Hepatoma",
        "Liver Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "DEB-TACE",
          "type": "DEVICE"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2015-11",
      "completion_date": "2017-06-05",
      "has_results": true,
      "last_update_posted_date": "2021-02-12",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02460991"
    },
    {
      "nct_id": "NCT04687969",
      "title": "Multimodal Machine Learning Characterization of Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenocarcinoma of Prostate",
        "Radical Prostatectomy",
        "Hepatocellular Carcinoma (HCC)",
        "Glioma",
        "Renal Cell Carcinoma (RCC)",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "[18F]DCFPyL",
          "type": "DRUG"
        },
        {
          "name": "PET/MRI scanner",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Ciprian Catana, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-10-23",
      "completion_date": "2024-08-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-15T00:16:31.850Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04687969"
    }
  ]
}